Phaseline

Targets › AVPR1B

AVPR1B (Vasopressin V1b receptor): drug programs, companies and trials

6 programs from 6 companies in 19 trials: 8 Phase 3, 5 Phase 4, 3 Phase 2, 3 Phase 1; Metabolic and endocrine, Genitourinary, Gastroenterology; next expected readout Jan 2027.

Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.; FUNCTION: (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, may recognize and internalize the complex formed by AVP/Arg-vasopressin, SARS-CoV-2 spike protein and secreted ACE2 through DNM2/dynamin 2-dependent endocytosis. (UniProt, P47901)

Open in Phaseline: the race on AVPR1B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TiohundraVasopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock …Jan 2027
Hamilton Health Sciences CorporationDesmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Chronic Kidney DiseasesFeb 2027
Assistance Publique - Hôpitaux de ParisDesmopressin Acetate
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3HyponatremiaDec 2027
Medical University of BialystokDesmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Kidney Biopsy–
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Desmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 2Cushing SyndromeOct 2028
PharmaINTerlipressin (PHIN-214)
Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent
AVPR1A, AVPR1B, AVPR2Phase 1Cirrhosis, Liver–

Conditions

Sepsis (2) Septic Shock (2) Hyponatremia (1) Kidney Biopsy (1) Cushing Syndrome (1) Chronic Kidney Diseases (1) Cirrhosis, Liver (1) Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial (1) Vasoplegic Syndrome of Cardiac Surgery (1) Retained Products of Conception (1) Shock (1) Scheduled Cardiac Surgery With Extracorporeal Circulation (1)

Modalities

small molecule (6)

Companies

Assistance Publique - Hôpitaux de Paris (1) Medical University of Bialystok (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Hamilton Health Sciences Corporation (1) PharmaIN (1) Tiohundra (1)

Related targets

AVPR2 (6) AVPR1A (6)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.